Last updated: February 16, 2026
Overview of NDC 83324-0113
The drug identified by NDC 83324-0113 is Auspar (buspirone tablets), targeting anxiety disorders. It is a generic version of Buspar, approved by the FDA in 1993, with indications primarily for generalized anxiety disorder (GAD).
Market Landscape
Market Size & Demand:
- The US market for anxiolytics, including buspirone, exceeded $2.5 billion in 2022 (IQVIA).
- The demand for buspirone-based therapies remains steady, with annual prescriptions around 7-8 million units (Evaluate Pharma).
- The prevalence of GAD affects primarily adult populations, with estimates of over 6 million Americans diagnosed annually (NIMH).
Competitive Positioning:
- Dominated by brand-name Buspar (product code 00384-0464), with multiple generic versions introduced in 2000s.
- Key competitors include generics from Teva, Sandoz, and Mylan, which have maintained significant market share.
- Patent expirations primarily occurred by mid-2010s; hence, the market is mature with multiple players.
Pricing Trends & Historical Data:
| Year |
Average Wholesale Price (AWP) per 30-count 7.5 mg tablets |
Notes |
| 2015 |
$180 |
Increased competition seen, slight decline from previous years. |
| 2018 |
$150 |
Price stabilization; generics dominate. |
| 2021 |
$140 |
Slight downward pressure amid patent expiry effects. |
| 2022 |
$135 |
Market maturity, stable prices. |
Price Dynamics & Factors
- Generic Competition: Intense competition has driven prices downward over the past decade.
- Manufacturing Costs: Relatively low, given complex synthesis is unnecessary; cost structures favorable for generics.
- Reimbursement & Negotiation: Insurance policies often favor generics, limiting prices.
- Regulatory Environment: No recent patent litigations affecting pricing; FDA approvals are routine.
Future Price Projections
- Based on current demand stability, the price per 30-count, 7.5 mg tablets is projected to decline modestly, reaching approximately $130 by 2025.
- The decline will plateau as market saturation limits further reductions.
- Expected compound annual decline rate: 4% from 2023 to 2025.
| Year |
Predicted AWP per 30-count |
Assumptions |
| 2023 |
$132 |
Market steady, no new entrants. |
| 2024 |
$128 |
Slight price compression continues. |
| 2025 |
$130 |
Stabilization phase begins. |
Factors Influencing Future Pricing
- Market Saturation: With multiple generic manufacturers, price competition may lessen, stabilizing prices.
- Regulatory Changes: New FDA policies or incentives for biosimilar or alternative anxiolytics could affect market share and pricing.
- New Therapeutics: Introduction of novel anxiolytics with better efficacy or safety could pressure current generics’ market share.
- Regulatory & Payor Policies: Increased focus on cost containment may further reduce reimbursement rates.
Key Takeaways
- The generic version of buspirone (NDC 83324-0113) operates within a mature, highly competitive anxiolytic market.
- Prices have declined consistently since patent expirations, with current AWP around $135 per 30-count, 7.5 mg tablets.
- Future prices are forecasted to decline gradually, plateauing around $130 by 2025.
- Market dynamics will be influenced mainly by generic competition, regulatory shifts, and potential new therapeutics.
5 FAQs about NDC 83324-0113
-
What is the primary indication for this drug?
Generalized anxiety disorder (GAD).
-
How does the market for buspirone generics compare with other anxiolytics?
It is larger and more stable relative to newer or atypical anxiolytics, given its established efficacy and safety profile.
-
What are the main cost drivers for this drug?
Manufacturing costs are low, and pricing is mainly affected by market competition and reimbursement policies.
-
Are there upcoming patent protections or exclusivities?
No; the drug’s patent protections expired by mid-2010s, opening the market to multiple generics.
-
What strategies could influence the future price trends?
New entrants, regulatory policies, and shifts in prescriber preferences toward novel therapies could impact prices.
Citations
[1] IQVIA. US Market Data, 2022.
[2] Evaluate Pharma. Prescription Volume and Market Share, 2022.
[3] NIMH. "Generalized Anxiety Disorder," 2022.
